Bridging the gaps in alzheimer's disease: a comprehensive review of current and emerging therapies.
Level 5 - mechanism / opinion, no new human data
Narrative review of disease mechanisms and therapeutic strategies without systematic review methodology.
PubMed 41870777 · doi:10.1007/s10787-026-02151-3
What was done
This is a narrative review examining the etiology, molecular mechanisms, genetic and environmental risk factors, and therapeutic landscape of Alzheimer's disease. The authors synthesized existing literature covering traditional symptomatic treatments, emerging disease-modifying pharmacotherapies, non-pharmacological interventions, and diagnostic biomarker advancements.
What was found
The abstract presents a qualitative overview of Alzheimer's disease pathogenesis (amyloid cascade, tau hyperphosphorylation, cholinergic deficit, vascular, and neuroinflammatory mechanisms) and treatment strategies. Aside from noting that Alzheimer's disease accounts for 60% to 80% of dementia cases globally, the abstract reports no empirical effect sizes, clinical trial outcome numbers, or quantitative comparative data.
Why it matters
The review maps the ongoing shift in Alzheimer's disease management from palliative symptom management toward multi-target disease-modifying agents and precision medicine. It collates diverse therapeutic targets into a single broad framework.
Limits
As a narrative review, the paper lacks systematic search criteria, quality appraisal of cited literature, and quantitative meta-analysis. The abstract provides no primary human clinical data, effect sizes, or comparative efficacy metrics for the discussed interventions.
Cited by
- supports Alzheimer's disease accounts for approximately 60% to 80% of all dementia cases.